Added to YB: 2026-06-09
Pitch date: 2026-04-09
RMD [bearish]
ResMed Inc.
+8.81%
current return
Author Info
No bio for this author
Company Info
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.
Market Cap
$30.1B
Pitch Price
$228.70
Price Target
118.00 (-43%)
Dividend
1.15%
EV/EBITDA
13.56
P/E
20.15
EV/Sales
5.30
Sector
Health Care Equipment and Supplies
Category
N/A
ResMed Inc. - $RMD (short)
RMD (short): Short on GLP-1 disruption of CPAP market (~90% of rev). GLP-1 use (15-20m US users, ~30m w/ new pill form) cutting CPAP demand: Komodo study shows 83% fewer CPAP starts; ATS study 79% lower CPAP. FY28 EPS could hit $10-11 vs $13.26 est. At 14-16x, 25-40% downside. Risks: GLP-1 side effects, re-rate to 30x. Catalysts: GLP-1 pill uptake, Philips reentry, Apnimed FDA approval.
Read full article (9 min)